Gadi Lachman Joins Srotas Health Board to Transform Clinical Trial Recruitment

Gadi Lachman Joins Srotas Health Board of Directors

In a significant move for the clinical research landscape, Gadi Lachman, the founder and former CEO of TriNetX, has been appointed to the Board of Directors at Srotas Health. This appointment comes at a crucial time as Srotas Health seeks to revolutionize clinical trial recruitment through its innovative AI technologies.

Background of Srotas Health

Established with the mission to streamline the clinical trial process, Srotas Health utilizes advanced AI to enhance the recruitment, feasibility, and patient engagement aspects of clinical trials. Their proprietary technology, developed over three years, is designed to address the persistent and time-consuming challenge of patient recruitment, a critical phase in clinical research that has remained largely unchanged for decades.

Lachman's Expertise

Having successfully led TriNetX, which has built global infrastructure connecting healthcare organizations, biopharma companies, and researchers across 19 countries, Lachman brings unparalleled expertise to Srotas Health. His deep understanding of the market dynamics and the challenges facing patient recruitment positions him uniquely to guide Srotas Health in executing its vision.

Lachman acknowledged the importance of this role, stating, “I am honored to join the Srotas Health journey at such an exciting moment. Applying AI to solve the last mile of patient recruitment for clinical trials is one of the most pragmatic implementations of AI I have seen in the pharma and real-world data space.” He emphasizes that this initiative holds significant implications for improving the recruitment process and ultimately benefiting patients.

The Current State of Clinical Trials

Historically, the landscape of patient recruitment in clinical trials has lagged behind advancements in science and technology. For instance, the landmark Salk polio trial in 1954 enlisted 1.8 million children using inefficient methods such as paper forms and phone calls. Remarkably, many clinical research sites today still rely on similar outdated practices, a reality Srotas Health aims to change.

By integrating AI directly into the recruitment process, Srotas Health is positioned to optimize workflows and enhance the experience for both researchers and patients. Their platform not only promises efficiency but also ensures patient data privacy through compliance with regulations such as HIPAA and GDPR.

Impact on Clinical Research

Srotas Health claims that sites using their AI-driven platform have observed a 60% increase in patient recruitment rates compared to previous methods. This kind of enhancement in recruitment efficiency can dramatically accelerate the timeline for clinical trials, ultimately leading to quicker access for patients to new therapies and medications.

The platform operates across more than 50 research sites in the US and UK, actively supporting over 60 clinical trials and processing millions of patient records. By eliminating the bottlenecks associated with traditional recruitment practices, Srotas Health signifies a paradigm shift in how clinical trials can be conducted moving forward.

Conclusion

Gadi Lachman's appointment is a promising development for Srotas Health as it endeavors to reshape clinical trial recruitment. With his vast experience and commitment to innovation, Lachman's involvement is expected to drive significant advancements in the way clinical trials are configured and executed, thereby improving efficiency and outcomes for patients in need. As the clinical research industry seeks to modernize and expand, Srotas Health stands at the forefront, equipped with the necessary tools and leadership to make a lasting impact.